Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcripts of Q4 & FY24 Earning call Held on May 28, 202404-06-2024
04-06-2024
Concord Biotech Ltd - 543960 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for 1575773 Ontario INC29-05-2024
Concord Biotech Shareholder Pares Stake For Rs 482 Crore
Ontario Inc. owned 5.39% in the Jhunjhunwala family-backed company as of March 2024.28-05-2024
Concord Biotech Ltd - 543960 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to the regulation 24A of the SEBI (LODR) Regulation (Amendment), 2018, Please find the enclosed annual secretarial compliance report for the year ended March 31, 2024. Kindly take the above on records.28-05-2024
Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to the provision of Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, and further to our intimation dated May 21, 2024 to the Stock exchanges regarding Earning call in respect of the audited (Standalone and Consolidated) Financial Results of the company for the fourth Quarter and year ended March 31, 2024, we wish to inform that the said Earning Call was held today at 04:00 PM (IST). The audio recording of the conference call has been hosted on the website of the company and link to access the said recording is as follows: - Link :- https://www.concordbiotech.com/public/assets/pdf/Q4FY24-earning-call-audio.mp3 Kindly take the above on records.28-05-2024
Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to regulation 30 of schedule III Part A (LODR) regulation 2015, Investor Presentation on financial results for the fourth quarter and year ended March 31, 2024 is enclosed. Kindly take the above on records.27-05-2024
Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to regulation of the SEBI (LODR) regulation, 2015, Please find the enclosed herewith the extracts of standalone and consolidated audited financial results for fourth quarter and year ended March 31, 2024 as published in Various Newspaper on May 24, 2024. Kindly take the above on records.24-05-2024
Concord Biotech Ltd - 543960 - Correction In Dividend % Mentioned In The Outcome Of Board Meeting Held Today I.E. Thursday, May 23, 2024- Audited Financial Results For The Quarter And Financial Year Ended On March 31, 2024
The Board of Directors ("the Board") as its meeting held on 23rd May, 2024 has recommended Dividend of Rs. 8.75 (@30%) per Equity Share of Face Value of Re. 1 Each Fully paid up for the Financial Year 2023-24, subject to approval by shareholders of the company at the ensuing AGM Due to typographical error the % was mentioned as 30% instead of 875% which is the correct figure.23-05-2024
Concord Biotech Ltd - 543960 - Corporate Action-Board approves Dividend
The Board of Directors ("the Board") at its meeting held on 23 May 2024 has recommended dividend of Rs. 8.75 (30%) per equity share of face value of Re. 1 each fully paid up for the financial year 2023-24, subject to approval by shareholders of the company at the ensuing AGM. Due to Typographical error the % was mentioned as 30% instead of 875% which is the correct figure.23-05-2024
Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
Subject to approval of members at the ensuing annual general meeting and upon recommendation of audit committee of the company, the board had approved appointment of BSR & Co LLP as statutory Auditor of the company for a first term of consecutive 5 Year in place of existing statutory auditors M/s Deloitte Haskins & Sell, Chartered Accountant, whose tenure is expiring at the ensuing Annual general meeting of the company.23-05-2024